[go: up one dir, main page]

UY26146A1 - Utilización de ácidos tranexamico para la preparación de una composición de fibrinógeno humano ley 17.164 - Google Patents

Utilización de ácidos tranexamico para la preparación de una composición de fibrinógeno humano ley 17.164

Info

Publication number
UY26146A1
UY26146A1 UY26146A UY26146A UY26146A1 UY 26146 A1 UY26146 A1 UY 26146A1 UY 26146 A UY26146 A UY 26146A UY 26146 A UY26146 A UY 26146A UY 26146 A1 UY26146 A1 UY 26146A1
Authority
UY
Uruguay
Prior art keywords
composition
preparation
law
human fibrinogen
human
Prior art date
Application number
UY26146A
Other languages
English (en)
Inventor
Pere Ristol Debart B Rodriguez
Ma Isabel Bravo Camison
Jesus Fernandez Rodriguez
Pere Ristol Debart
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of UY26146A1 publication Critical patent/UY26146A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención se refiere a una utilización del ácido tranexámico para la preparación de una composición de fibrinógeno humano obtenido a partir de plasma humano o mediante métodos de tecnología recombinante o transgénica, con la adición simultánea de albúmina humana, para acortar el tiempo de solubilización al anadir un disolvente fisiológicamente compatible y a la composición de fibrinógeno.
UY26146A 1999-05-31 2000-05-16 Utilización de ácidos tranexamico para la preparación de una composición de fibrinógeno humano ley 17.164 UY26146A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009901175A ES2156731B1 (es) 1999-05-31 1999-05-31 Utilizacion del acido tranexamico para la preparacion de una composicion de fibrinogeno humano.

Publications (1)

Publication Number Publication Date
UY26146A1 true UY26146A1 (es) 2000-12-29

Family

ID=8308626

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26146A UY26146A1 (es) 1999-05-31 2000-05-16 Utilización de ácidos tranexamico para la preparación de una composición de fibrinógeno humano ley 17.164

Country Status (7)

Country Link
EP (1) EP1057490A3 (es)
JP (1) JP2001019644A (es)
AR (1) AR024551A1 (es)
ES (1) ES2156731B1 (es)
HU (1) HUP0001841A2 (es)
SK (1) SK7582000A3 (es)
UY (1) UY26146A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2214967B1 (es) * 2003-03-06 2005-06-16 Probitas Pharma, S.A Procedimiento para la eliminacion de virus en soluciones de fibrinogeno y fibrinogeno obtenido por dicho procedimiento.
RU2484817C1 (ru) * 2012-03-11 2013-06-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Астраханская государственная медицинская академия" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО АГМА Минздравсоцразвития России) Способ профилактики повышенной кровопотери и коагулопатического кровотечения при вагинальном родоразрешении в раннем послеродовом периоде
EP2695605B1 (en) * 2012-08-07 2017-05-03 Parapharm Development Ltd. Tranexamic acid composition
KR101841587B1 (ko) * 2016-01-12 2018-05-14 주식회사 녹십자홀딩스 피브리노겐의 정제방법
EP4681713A2 (en) * 2017-08-27 2026-01-21 Anti-Viral Technologies, LLC Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics
CN116115561A (zh) * 2023-03-17 2023-05-16 湖南浩森制药有限公司 一种氨甲环酸注射液及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2101811B (en) * 1981-06-30 1985-01-03 Racal Dana Instr Ltd Improvements in and relating to the screening of electrical circuit arrangements
DE3203775A1 (de) * 1982-02-04 1983-08-11 Behringwerke Ag, 3550 Marburg Fibrinogenzubereitung, verfahen zu ihrer herstellungund ihre verwendung
JPH08512215A (ja) * 1993-03-30 1996-12-24 オパーバス・ホールディング・ビー・ブイ 二成分フィブリングルー
GB9424732D0 (en) * 1994-12-08 1995-02-08 Common Services Agency Heat treated blood plasma proteins
EP0856317A1 (en) * 1997-01-31 1998-08-05 Omrix Biopharmaceuticals S.A. A stabilized mixture comprising fibrinogen
AU8336098A (en) * 1997-06-05 1998-12-21 Omrix Biopharmaceuticals S.A. Fibrinogen concentrate from human plasma

Also Published As

Publication number Publication date
ES2156731A1 (es) 2001-07-01
EP1057490A3 (en) 2002-04-03
JP2001019644A (ja) 2001-01-23
ES2156731B1 (es) 2002-02-16
SK7582000A3 (en) 2001-05-10
HUP0001841A2 (en) 2002-09-28
AR024551A1 (es) 2002-10-16
HU0001841D0 (en) 2000-07-28
EP1057490A2 (en) 2000-12-06

Similar Documents

Publication Publication Date Title
CY1110602T1 (el) Φαρμακευτικες συνθεσεις υπο μορφη γελης ή διαλυματος με βαση τη διυδροτεστοστερονη, μεθοδοι παρασκευης και χρησεις τους
ATE490262T1 (de) Abschwächung der immunogenizität von fusionsproteinen
CY1119243T1 (el) Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf
DK1094816T3 (da) Biphenylsulfonamider som dobbelte angiotensin-endothelin-receptorantagonister
BRPI0409133A (pt) formulações farmacêuticas contendo metilnaltrexona
ATE411082T1 (de) Neue verwendung von kurzkettigen carbonsäuren
ES2721172T3 (es) Una nueva clase de moléculas terapéuticas a base de proteínas
PA8575701A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
ATE270557T1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
IL149459A0 (en) Recombinant gelatins
FI916129A0 (fi) Substituerade imidazoler.
NO20071490L (no) Farmasoytisk aktive isoindolderivater
BR0209685A (pt) Derivado de um peptìdeo insulinotrópico e sais farmaceuticamente aceitáveis produzidos a partir do mesmo, método de produção de derivado de peptìdeo insulinotrópico e uso de um derivado de peptìdeo insulinotrópico e de sais farmaceuticamente aceitáveis
WO2002011764A3 (en) PHARMACEUTICAL COMPOSITIONS
BR0211761A (pt) depsipeptìdeos e processos para preparar os mesmos
TR199900486T2 (xx) Aziniloksi ve fenoksi-diaril-karbonasit t�revleri.
ATE211391T1 (de) Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
ES2156642T3 (es) Composicion que comprende un derivado de acido cinamico y un polimero poliaminado.
UY26146A1 (es) Utilización de ácidos tranexamico para la preparación de una composición de fibrinógeno humano ley 17.164
ATE77957T1 (de) Peptid-zusammensetzung fuer die herstellung von malaria-impfstoff, sowie fuer die vorbereitung von diagnostischen einzelteilen fuer den nachweis von malaria-aehnlichen krankheiten.
BR0009810A (pt) Copolìmeros com subunidades anfifìlicas, processo para sua preparação e seu emprego
FR2825621B1 (fr) Composition cosmetique pour les ongles, sans phtalate, sans camphre ni solvant aromatique
EA199700243A1 (ru) Производное аминотетралина для лечения сердечно-сосудистых заболеваний
BRPI0406734A (pt) Composição termiticida, e, método para controlar térmitas
BR0010499A (pt) Agentes endoparasiticidas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20101201